

REMARKS/ARGUMENTS

Claim 1 is currently amended. Support for the amendment can be found in the specification at page 19, line 33 through page 20, line 11.

Claims 1 through 27 are presently pending.

No new subject matter has been added.

Current claims 1 through 27 mirror those claims issued in US Patent No. 6,329,425, however, a pharmaceutically acceptable carrier is not included. A terminal disclaimer has already been filed for US Patent No. 6,329,425.

Rejection of Claims 1 through 27 under 35 U.S.C. § 112, First Paragraph

Claims 1 through 27 stand rejected under 35 U.S.C. § 112, first paragraph, for the reasons set forth on pages 3 through 5 of the office action dated August 29, 2005.

Applicant respectfully traverses the rejection, however, in order to facilitate prosecution of the application, the claims have been amended to overcome the rejection. No prejudice should be inferred by the amendment. Applicant reserves the right to prosecute the original claims in a continuation application.

Reconsideration and withdrawal of this rejection is respectfully requested.

Rejection of Claims 1 through 14 under 35 U.S.C. § 102(b)

Claims 1 through 14 were rejected under 35 U.S.C. § 102(b) as being anticipated by WO 90/13292, hereinafter "the WO publication".

Claim 1 was amended to include the phrase "[A] method for treating or preventing a disease or condition associated with columnar epithelial inflammation in a subject.

The WO publication fails to teach or suggest a method for treating or preventing a disease or condition associated with columnar epithelial inflammation in a subject.

Claims 2 through 27 help further define the invention and are all dependent from claim 1.

Reconsideration and withdrawal of this rejection is respectfully requested.

CONCLUSION


This application now stands in allowable form and reconsideration and allowance is respectfully requested. If a telephonic consultation would help to expedite the processing of the application, the Examiner is urged to contact the attorney below at the Examiner's convenience.

No fees are considered due at this time other than the fee due for the extension of time. The Commissioner is hereby authorized to charge any deficiencies or credit any overpayments to Deposit Account No. 04-1420.

Respectfully submitted,

DORSEY & WHITNEY LLP
Customer Number 25763

Date: June 6, 2006

By: 

Scott D. Rothenberger, Esq.
Reg. No. 41,277
Phone: (612) 340-8819